Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Invirase
2. Monomethanesulfonate, Saquinavir
3. Ro 31 8959
4. Ro 31-8959
5. Ro 318959
6. Saquinavir
7. Saquinavir Monomethanesulfonate
8. Saquinivir
1. 149845-06-7
2. Invirase
3. Fortovase
4. Saquinavir Mesilate
5. Saquinavir, Mesylate
6. Ro 31-8959/003
7. Saquinavir Methanesulfonate Salt
8. Uhb9z3841a
9. Butanediamide, N1-[(1s,2r)-3-[(3s,4as,8as)-3-[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1h)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2s)-, Methanesulfonate (1:1)
10. Chebi:32121
11. (2s)-n-[(2s,3r)-4-[(3s,4as,8as)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide;methanesulfonic Acid
12. (s)-n1-((2s,3r)-4-((3s,4as,8as)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1h)-yl)-3-hydroxy-1-phenylbutan-2-yl)-2-(quinoline-2-carboxamido)succinamide Methanesulfonate
13. Ncgc00091469-01
14. Ro-318959003
15. Dsstox_cid_3835
16. Ro-31-8959/003
17. Saquinavir Mesilate (jan)
18. Dsstox_rid_77202
19. Dsstox_gsid_23835
20. Saquinavir Mesilate [jan]
21. Saquinavir Mesylate [usan]
22. Saquinavir Monomethanesulfonate Salt
23. Unii-uhb9z3841a
24. Saquinavir Mesylate [usan:usp]
25. Invirase (tn)
26. N1-{(1s,2r)-1-benzyl-3-[(3s,4as,8as)-3-[(tert-butylamino)carbonyl]octahydroisoquinolin-2(1h)-yl]-2-hydroxypropyl}-n2-(quinolin-2-ylcarbonyl)-l-aspartamide Methanesulfonate (salt)
27. Cas-149845-06-7
28. Saquinavir Mesylate (aids Initiative)
29. Sqv
30. Saquinavir Mesylate (usp)
31. Saquinavir Mesylate- Bio-x
32. Schembl42352
33. (s)-n-((alphas)-alpha-((1r)-2-((3s,4as,8as)-3-(tert-butylcarbamoyl)octahydro-2(1h)-isoquinolyl)-1-hydroxyethyl)phenethyl)-2-quinaldamidosuccinamide Monomethanesulfonate (salt)
34. Mls001401395
35. Chembl282042
36. Dtxsid9023835
37. Hms1571o10
38. Hms2051d04
39. Hms2098o10
40. Hms2231c15
41. Hms3715o10
42. Saquinavir Mesylate [vandf]
43. Saquinavir Mesilate [mart.]
44. Tox21_111137
45. Tox21_202533
46. Saquinavir Mesilate [who-dd]
47. Saquinavir Mesilate [who-ip]
48. Saquinavir Mesylate [usp-rs]
49. Akos015962362
50. Ac-1333
51. Ccg-100992
52. Ks-1110
53. Nc00242
54. Ncgc00260082-01
55. Saquinavir Mesylate [orange Book]
56. (2s)-n1[(1s,2r)-3-[(3s,4as,8as)-3-[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2-(1h)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]butanediamide Mesylate
57. Bs164392
58. Butanediamide, N(sup 1)-(3-(3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1h)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (3s-(2(1r*(r*),2s*),3alpha,4abeta,8abeta))-, Monomethanesulfonate (salt)
59. Butanediamide, N1-((1s,2r)-3-((3s,4as,8as)-3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1h)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (2s)-, Monomethanesulfonate (salt)
60. R-56
61. Saquinavir Mesilate [ep Monograph]
62. Saquinavir Mesylate [usp Impurity]
63. Smr000469290
64. Saquinavir Mesylate [usp Monograph]
65. Saquinavir Methanesulfonate Salt [mi]
66. Ro-31-8959-003
67. Saquinavir Mesylate, >=98% (hplc), Powder
68. D01160
69. 845s067
70. Sr-01000763454
71. J-008634
72. Sr-01000763454-4
73. Q27114794
74. Saquinavir Mesilate, European Pharmacopoeia (ep) Reference Standard
75. Saquinavir Mesylate, United States Pharmacopeia (usp) Reference Standard
76. Saquinavir For System Suitability, European Pharmacopoeia (ep) Reference Standard
77. (2s)-n1-[(1s,2r)-3-[(3s,4as,8as)-3-[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1h)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]butanediamide Methanesulfonate
78. (s)-n-((.alpha.s)-.alpha.-((1r)-2-((3s,4as,8as)-3-(tert-butylcarbamoyl)octahydro-2(1h)-isoquinolyl)-1-hydroxyethyl)phenethyl)-2-quinaldamidosuccinamide Monomethanesulfonate
79. (s)-n-((.alpha.s)-.alpha.-((1r)-2-((3s,4as,8as)-3-(tert-butylcarbamoyl)octahydro-2(1h)-isoquinolyl)-1-hydroxyethyl)phenethyl)-2-quinaldamidosuccinamide Monomethanesulphonate
80. Butanediamide, N(sup 1)-(3-(3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1h)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (3s-(2(1r*(r*),2s*),3.alpha.,4a.beta.,8a.beta.))-, Monomethanesulfonate
81. Butanediamide, N(sup 1)-(3-(3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1h)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (3s-(2(1r*(r*),2s*),3.alpha.,4a.beta.,8a.beta.))-, Monomethanesulphonate
82. N-t-butyl-decahydro-2-[2(r)-hydroxy-4-phenyl-3(s)-[[n-(2-quinolylcarbonyl)-l-asparaginyl]amino]butyl]-(4as,8as)-isoquinoline-3(s)-carboxamide Methanesulphonate
Molecular Weight | 766.9 g/mol |
---|---|
Molecular Formula | C39H54N6O8S |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 13 |
Exact Mass | 766.37238388 g/mol |
Monoisotopic Mass | 766.37238388 g/mol |
Topological Polar Surface Area | 230 Ų |
Heavy Atom Count | 54 |
Formal Charge | 0 |
Complexity | 1230 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 6 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Invirase |
PubMed Health | Saquinavir (By mouth) |
Drug Classes | Antiretroviral Agent |
Drug Label | INVIRASE brand of saquinavir mesylate is an inhibitor of the human immunodeficiency virus (HIV) protease. INVIRASE is available as light brown and green, opaque hard gelatin capsules for oral administration in a 200-mg strength (as saquinavir free ba... |
Active Ingredient | Saquinavir mesylate |
Dosage Form | Tablet; Capsule |
Route | Oral |
Strength | eq 500mg base; eq 200mg base |
Market Status | Prescription |
Company | Hoffman La Roche; Hoffmann La Roche |
2 of 2 | |
---|---|
Drug Name | Invirase |
PubMed Health | Saquinavir (By mouth) |
Drug Classes | Antiretroviral Agent |
Drug Label | INVIRASE brand of saquinavir mesylate is an inhibitor of the human immunodeficiency virus (HIV) protease. INVIRASE is available as light brown and green, opaque hard gelatin capsules for oral administration in a 200-mg strength (as saquinavir free ba... |
Active Ingredient | Saquinavir mesylate |
Dosage Form | Tablet; Capsule |
Route | Oral |
Strength | eq 500mg base; eq 200mg base |
Market Status | Prescription |
Company | Hoffman La Roche; Hoffmann La Roche |
Invirase is indicated for the treatment of HIV-1-infected adult patients. Invirase should only be given in combination with ritonavir and other antiretroviral medicinal products.
Cytochrome P-450 CYP3A Inhibitors
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP3A. (See all compounds classified as Cytochrome P-450 CYP3A Inhibitors.)
HIV Protease Inhibitors
Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. (See all compounds classified as HIV Protease Inhibitors.)
J05AE01
Related Excipient Companies
Excipients by Applications
Global Sales Information
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
52
PharmaCompass offers a list of Saquinavir Mesylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Saquinavir Mesylate manufacturer or Saquinavir Mesylate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Saquinavir Mesylate manufacturer or Saquinavir Mesylate supplier.
PharmaCompass also assists you with knowing the Saquinavir Mesylate API Price utilized in the formulation of products. Saquinavir Mesylate API Price is not always fixed or binding as the Saquinavir Mesylate Price is obtained through a variety of data sources. The Saquinavir Mesylate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A 3B2-0203 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 3B2-0203, including repackagers and relabelers. The FDA regulates 3B2-0203 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 3B2-0203 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of 3B2-0203 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A 3B2-0203 supplier is an individual or a company that provides 3B2-0203 active pharmaceutical ingredient (API) or 3B2-0203 finished formulations upon request. The 3B2-0203 suppliers may include 3B2-0203 API manufacturers, exporters, distributors and traders.
click here to find a list of 3B2-0203 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A 3B2-0203 DMF (Drug Master File) is a document detailing the whole manufacturing process of 3B2-0203 active pharmaceutical ingredient (API) in detail. Different forms of 3B2-0203 DMFs exist exist since differing nations have different regulations, such as 3B2-0203 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A 3B2-0203 DMF submitted to regulatory agencies in the US is known as a USDMF. 3B2-0203 USDMF includes data on 3B2-0203's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The 3B2-0203 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of 3B2-0203 suppliers with USDMF on PharmaCompass.
A 3B2-0203 written confirmation (3B2-0203 WC) is an official document issued by a regulatory agency to a 3B2-0203 manufacturer, verifying that the manufacturing facility of a 3B2-0203 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting 3B2-0203 APIs or 3B2-0203 finished pharmaceutical products to another nation, regulatory agencies frequently require a 3B2-0203 WC (written confirmation) as part of the regulatory process.
click here to find a list of 3B2-0203 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing 3B2-0203 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for 3B2-0203 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture 3B2-0203 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain 3B2-0203 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a 3B2-0203 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of 3B2-0203 suppliers with NDC on PharmaCompass.
3B2-0203 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 3B2-0203 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 3B2-0203 GMP manufacturer or 3B2-0203 GMP API supplier for your needs.
A 3B2-0203 CoA (Certificate of Analysis) is a formal document that attests to 3B2-0203's compliance with 3B2-0203 specifications and serves as a tool for batch-level quality control.
3B2-0203 CoA mostly includes findings from lab analyses of a specific batch. For each 3B2-0203 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
3B2-0203 may be tested according to a variety of international standards, such as European Pharmacopoeia (3B2-0203 EP), 3B2-0203 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (3B2-0203 USP).